Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APHATSE:AUPNASDAQ:CARANYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHAAphria$15.38$15.48$2.78▼$32.29$4.87B2.6721.83 million shsN/AAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$31.32$24.33M0.4123,105 shs237,144 shsPBHPrestige Consumer Healthcare$80.52+1.2%$83.60$62.35▼$90.04$3.99B0.47287,807 shs270,919 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHAAphria0.00%0.00%0.00%0.00%0.00%AUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%-3.80%-11.19%-33.99%PBHPrestige Consumer Healthcare+1.32%+0.53%-5.23%+4.85%+14.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHAAphriaN/AN/AN/AN/AN/AN/AN/AN/AAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics3.7457 of 5 stars3.05.00.04.22.20.80.0PBHPrestige Consumer Healthcare4.1597 of 5 stars2.32.01.73.53.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHAAphria 0.00N/AN/AN/AAUPAurinia Pharmaceuticals 0.00N/AN/AN/ACARACara Therapeutics 2.00Hold$83.52∞ UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3315.91% UpsideCurrent Analyst Ratings BreakdownLatest CARA, APHA, PBH, and AUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.002/13/2025PBHPrestige Consumer HealthcareOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$87.00 ➝ $93.002/7/2025PBHPrestige Consumer HealthcareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$93.00 ➝ $100.002/7/2025PBHPrestige Consumer HealthcareDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$95.00 ➝ $104.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHAAphria$405.96M12.00$0.09 per share166.43$4.80 per share3.20AUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00PBHPrestige Consumer Healthcare$1.12B3.57$4.73 per share17.03$36.10 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHAAphria-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/AAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%5/12/2025 (Estimated)PBHPrestige Consumer Healthcare$209.34M$4.2718.8616.922.6919.13%12.36%6.39%5/8/2025 (Estimated)Latest CARA, APHA, PBH, and AUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30N/AN/AN/A$289.36 millionN/A2/6/2025Q3 2025PBHPrestige Consumer Healthcare$1.18$1.22+$0.04$1.22$287.07 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHAAphriaN/AN/AN/AN/AN/AAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.36%N/A44.50%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHAAphria0.252.361.17AUPAurinia Pharmaceuticals2.6911.9311.02CARACara TherapeuticsN/A4.774.71PBHPrestige Consumer Healthcare0.563.682.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHAAphria10.30%AUPAurinia PharmaceuticalsN/ACARACara Therapeutics44.66%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipAPHAAphriaN/AAUPAurinia PharmaceuticalsN/ACARACara Therapeutics3.10%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHAAphria1,200316.80 millionN/AOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableCARACara Therapeutics804.57 million4.43 millionOptionablePBHPrestige Consumer Healthcare54049.54 million48.75 millionOptionableCARA, APHA, PBH, and AUP HeadlinesRecent News About These CompaniesBarclays PLC Has $8.72 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 26 at 4:07 AM | marketbeat.comZacks Research Has Positive Outlook for PBH FY2025 EarningsApril 25 at 3:31 AM | americanbankingnews.comDimensional Fund Advisors LP Trims Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 24 at 5:02 AM | marketbeat.comKayne Anderson Rudnick Investment Management LLC Purchases New Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 23 at 6:01 AM | marketbeat.comFarringdon Capital Ltd. Takes $250,000 Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 22, 2025 | marketbeat.comEnvestnet Asset Management Inc. Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 19, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 18, 2025 | marketbeat.com3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff WoesApril 17, 2025 | zacks.comIs Prestige Consumer Healthcare Inc. (NYSE:PBH) Trading At A 43% Discount?April 16, 2025 | finance.yahoo.comTownsquare Capital LLC Acquires 9,516 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)April 16, 2025 | marketbeat.comWells Fargo & Company MN Boosts Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 16, 2025 | marketbeat.comAnalysts Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $93.33April 16, 2025 | americanbankingnews.comRenaissance Technologies LLC Trims Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 15, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 15, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Invesco Ltd.April 15, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Wellington Management Group LLPApril 15, 2025 | marketbeat.comAlliancebernstein L.P. Cuts Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 15, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by LSV Asset ManagementApril 14, 2025 | marketbeat.comLPL Financial LLC Has $2.75 Million Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 14, 2025 | marketbeat.comF M Investments LLC Sells 108,608 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)April 13, 2025 | marketbeat.comBessemer Group Inc. Increases Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)April 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, APHA, PBH, and AUP Company DescriptionsAphria NASDAQ:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Aurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Prestige Consumer Healthcare NYSE:PBH$80.52 +0.99 (+1.24%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$79.64 -0.88 (-1.09%) As of 04/25/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
